I-Mab to Concentrate on Five Clinical-Stage Candidates, Will Out-license International Rights

I-Mab said it would concentrate its drug development efforts on five key candidates, for which it will seek international partners once the candidates show Phase I or II proof of concept. It plans to out-license ex-China rights, while retaining China rights, though it will also partner commercialization in China to avoid the cost of building a sales force. The detailed presentation of the company’s assets seems an oblique denial that I-Mab is seeking to sell the entire company, a possibility raised in recent press reports. I-Mab pointed out that it has almost $600 million in cash, enough to support three years of operations. More details....

Stock Symbol: (NSDQ: IMAB)

Share this with colleagues: